TWI560187B - Tri- and tetracyclic pyrazolo[3,4-b]pyridine compounds as antineoplastic agent - Google Patents

Tri- and tetracyclic pyrazolo[3,4-b]pyridine compounds as antineoplastic agent

Info

Publication number
TWI560187B
TWI560187B TW101112790A TW101112790A TWI560187B TW I560187 B TWI560187 B TW I560187B TW 101112790 A TW101112790 A TW 101112790A TW 101112790 A TW101112790 A TW 101112790A TW I560187 B TWI560187 B TW I560187B
Authority
TW
Taiwan
Prior art keywords
tetracyclic
pyrazolo
tri
antineoplastic agent
pyridine compounds
Prior art date
Application number
TW101112790A
Other languages
English (en)
Chinese (zh)
Other versions
TW201247665A (en
Inventor
Remi Rabot
Karim Bedjeguelal
El Bachir Kaloun
Philippe Schmitt
Nicolas Rahier
Patrice Mayer
Emmanuel Fournier
Original Assignee
Pf Medicament
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pf Medicament filed Critical Pf Medicament
Publication of TW201247665A publication Critical patent/TW201247665A/zh
Application granted granted Critical
Publication of TWI560187B publication Critical patent/TWI560187B/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/14—Ortho-condensed systems
    • C07D491/147—Ortho-condensed systems the condensed system containing one ring with oxygen as ring hetero atom and two rings with nitrogen as ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/12—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains three hetero rings
    • C07D493/14—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
TW101112790A 2011-04-12 2012-04-11 Tri- and tetracyclic pyrazolo[3,4-b]pyridine compounds as antineoplastic agent TWI560187B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR1153200A FR2974088A1 (fr) 2011-04-12 2011-04-12 Composes pyrazolo[3,4-b]pyridines tri- et tetracycliques comme agent anticancereux

Publications (2)

Publication Number Publication Date
TW201247665A TW201247665A (en) 2012-12-01
TWI560187B true TWI560187B (en) 2016-12-01

Family

ID=44512344

Family Applications (1)

Application Number Title Priority Date Filing Date
TW101112790A TWI560187B (en) 2011-04-12 2012-04-11 Tri- and tetracyclic pyrazolo[3,4-b]pyridine compounds as antineoplastic agent

Country Status (15)

Country Link
US (1) US9085575B2 (OSRAM)
EP (1) EP2697222A1 (OSRAM)
JP (1) JP5972964B2 (OSRAM)
KR (1) KR20140023341A (OSRAM)
CN (1) CN103534254B (OSRAM)
AR (1) AR085987A1 (OSRAM)
AU (1) AU2012241891B2 (OSRAM)
BR (1) BR112013026355A2 (OSRAM)
CA (1) CA2832704A1 (OSRAM)
FR (1) FR2974088A1 (OSRAM)
MX (1) MX2013011854A (OSRAM)
RU (1) RU2013148922A (OSRAM)
TW (1) TWI560187B (OSRAM)
WO (1) WO2012140114A1 (OSRAM)
ZA (1) ZA201307783B (OSRAM)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012088266A2 (en) 2010-12-22 2012-06-28 Incyte Corporation Substituted imidazopyridazines and benzimidazoles as inhibitors of fgfr3
ES2984771T3 (es) 2012-06-13 2024-10-31 Incyte Holdings Corp Compuestos tricíclicos sustituidos como inhibidores de FGFR
WO2014026125A1 (en) 2012-08-10 2014-02-13 Incyte Corporation Pyrazine derivatives as fgfr inhibitors
US9266892B2 (en) 2012-12-19 2016-02-23 Incyte Holdings Corporation Fused pyrazoles as FGFR inhibitors
EA035095B1 (ru) 2013-04-19 2020-04-27 Инсайт Холдингс Корпорейшн Бициклические гетероциклы в качестве ингибиторов fgfr
US10053477B2 (en) 2014-07-04 2018-08-21 Qilu Pharmaceutical Co., Ltd. Spirocyclic aryl phosphorus oxide and aryl phosphorus sulfide
CN104447736B (zh) * 2014-10-14 2016-06-08 雅安职业技术学院 一种veranamine的合成方法
US10851105B2 (en) 2014-10-22 2020-12-01 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
US9974784B2 (en) * 2015-01-21 2018-05-22 The Texas A&M University System Inhibitors of activin-like receptor kinases
EA038045B1 (ru) 2015-02-20 2021-06-28 Инсайт Корпорейшн Бициклические гетероциклы в качестве ингибиторов fgfr
MA41551A (fr) 2015-02-20 2017-12-26 Incyte Corp Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
US9580423B2 (en) 2015-02-20 2017-02-28 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
AR111960A1 (es) 2017-05-26 2019-09-04 Incyte Corp Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
US11174257B2 (en) 2018-05-04 2021-11-16 Incyte Corporation Salts of an FGFR inhibitor
RS66310B1 (sr) 2018-05-04 2025-01-31 Incyte Corp Čvrsti oblici inhibitora fgfr i procesi za njegovu pripremu
WO2020185532A1 (en) 2019-03-08 2020-09-17 Incyte Corporation Methods of treating cancer with an fgfr inhibitor
WO2021007269A1 (en) 2019-07-09 2021-01-14 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
WO2021067374A1 (en) 2019-10-01 2021-04-08 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
PH12022550892A1 (en) 2019-10-14 2023-05-03 Incyte Corp Bicyclic heterocycles as fgfr inhibitors
US11566028B2 (en) 2019-10-16 2023-01-31 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
AU2020395185A1 (en) 2019-12-04 2022-06-02 Incyte Corporation Derivatives of an FGFR inhibitor
EP4069696A1 (en) 2019-12-04 2022-10-12 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
US12012409B2 (en) 2020-01-15 2024-06-18 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
CA3179671A1 (en) * 2020-08-07 2022-02-10 Abm Therapeutics Corporation Kinase inhibitors and uses thereof
JP2024513575A (ja) 2021-04-12 2024-03-26 インサイト・コーポレイション Ｆｇｆｒ阻害剤及びネクチン－４標的化剤を含む併用療法
WO2022261160A1 (en) 2021-06-09 2022-12-15 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
TW202313610A (zh) 2021-06-09 2023-04-01 美商英塞特公司 作為ｆｇｆｒ抑制劑之三環雜環

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070032515A1 (en) * 2003-07-23 2007-02-08 Exelixis, Inc. Anaplastic lymphoma kinase modulators and methods of use

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1919924A2 (en) * 2005-08-16 2008-05-14 Irm, Llc Compounds and compositions as protein kinase inhibitors
CN101525497B (zh) * 2008-03-06 2012-07-04 中国科学院理化技术研究所 吡唑啉吡啶并苯并香豆素荧光染料衍生物及其合成方法和用途
US20100113415A1 (en) * 2008-05-29 2010-05-06 Rajapakse Hemaka A Epha4 rtk inhibitors for treatment of neurological and neurodegenerative disorders and cancer

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070032515A1 (en) * 2003-07-23 2007-02-08 Exelixis, Inc. Anaplastic lymphoma kinase modulators and methods of use

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Jan Svetlik et al. Monastrol analogs: A synthesis of pyrazolopyridine, benzopyranopyrazolopyridine, and oxygen-bridged azolopyrimidine derivatives and their biological screening. Bioorganic & Medicinal Chemistry Letters Volume 20, Issue 14, 15 July 2010, Pages 4073–4076 *

Also Published As

Publication number Publication date
CA2832704A1 (en) 2012-10-18
CN103534254B (zh) 2015-11-25
KR20140023341A (ko) 2014-02-26
ZA201307783B (en) 2015-01-28
WO2012140114A1 (en) 2012-10-18
MX2013011854A (es) 2013-11-01
AU2012241891B2 (en) 2016-06-16
FR2974088A1 (fr) 2012-10-19
CN103534254A (zh) 2014-01-22
US9085575B2 (en) 2015-07-21
TW201247665A (en) 2012-12-01
RU2013148922A (ru) 2015-05-20
US20140031362A1 (en) 2014-01-30
HK1190397A1 (zh) 2014-07-04
BR112013026355A2 (pt) 2016-12-27
AU2012241891A1 (en) 2013-10-31
JP5972964B2 (ja) 2016-08-17
AR085987A1 (es) 2013-11-13
JP2014510774A (ja) 2014-05-01
EP2697222A1 (en) 2014-02-19

Similar Documents

Publication Publication Date Title
TWI560187B (en) Tri- and tetracyclic pyrazolo[3,4-b]pyridine compounds as antineoplastic agent
IL227496B (en) Pyrazolo[4,3–b]pyridines are converted as drugs
IL234485A (en) Compounds based on imidazo [2,1 – b] pyridazine
IL266285A (en) Methods for the production of tian compounds [d - 3,2] pyrimidine
PT2794611T (pt) Pirazolo[1,5-a]pirimidinas como agentes antivirais
IL235819A0 (en) Preparation of pyrrolo[b–3,2]pyridines
ZA201506570B (en) 2-phenylimidazo[1,2-a]pyrimidines as imaging agents
IL222977A0 (en) Novel 3,5- disubstituted-3 h-imidazolo[5-b]pyridine and 3,5-disubstituted-3h-[1.2.3]triazolo[4,5]py
PL2857404T3 (pl) POCHODNE IMIDAZO[1,2-b]PIRYDAZYNY JAKO INHIBITORY KINAZY
IL221479A0 (en) Triazolo [4,5-b] pyridin derivatives
SI2671884T1 (sl) Novi derivati 6,11-dihidro-5H-benzo(d)imidazo(1,2-a)azepinov kot ligandi receptorjev histamina H4
ZA201206630B (en) Hetaryl-[1,8]naphthyridine derivatives
ZA201307511B (en) Pyrido [2,3-b] pyrazine derivatives and their therapeutical uses
IL232717A0 (en) 3-cyanoaryl-h1-pyrrolo[b-3,2]pyridine derivatives
HUE042978T2 (hu) Antibakteriális ciklopenta[c]pirrol-szubsztituált 3,4-dihidro-1H-[1,8]naftiridon-származékok
ZA201406323B (en) Triazolo[4,5-d]pyrimidine derivatives
IL229993A (en) 8 - Alkoxy [1,2,4] triazolo [5,1 – c] pyrimidine– 2
ZA201403441B (en) [1,2,3]triazolo[4,5-d]pyrimidine derivatives as agonists of the cannabinoid
PL2694513T3 (pl) Pochodne pirazolopirymidynowe
ZA201304074B (en) Pyrazino[2,3-d]isoxazole derivative
EP2565194A4 (en) IMIDAZO [1,2-a] PYRIDINE DERIVATIVE
BR112013013282A2 (pt) compostos de oxazolo[5,4-b]piridin-5-ila
EP2651937B8 (en) Imidazo[4,5-c]quinolin-1-yl derivative useful in therapy
PT2729473E (pt) Derivados de ácido carboxílico com um anel oxazolo[5,4-b]piridina
AU2011246168A1 (en) Imidazo[1,2-a]pyridine derivative

Legal Events

Date Code Title Description
MM4A Annulment or lapse of patent due to non-payment of fees